PremiumWeekend UpdatesMerck, Regeneron, Cellectar, Humacyte, Foot Locker: Trending by Analysts Sector Spotlight: Trump executive order targets drug prices Mixed options sentiment in Merck (MRK), with shares up $1.25 (+1.68%) near $76.06 PremiumThe FlyFDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma Jefferies not seeing significant impact to Merck, Bristol from draft guidance UnitedHealth, Wayfair downgraded: Wall Street’s top analyst calls PremiumThe FlyOption traders moderately bearish in Merck (MRK), with shares down $-3.23 (-4.02%) near $77.20. Trump’s drug-price crackdown may lead to minor concessions, WSJ reports Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices 
